Esperion Therapeutics, Inc. (ESPR) Covered Calls

Esperion Therapeutics, Inc. is a pharmaceutical company dedicated to the development and commercialization of innovative, oral, low-density lipoprotein cholesterol lowering therapies. The firm focuses on addressing the needs of patients with hypercholesterolemia and cardiovascular disease who are unable to achieve their goals with existing treatments. By leveraging its expertise in ACLY biology, the company provides effective non-statin options for at-risk users.

You can sell covered calls on Esperion Therapeutics, Inc. to lower risk and earn monthly income. Born To Sell's covered call screener gives you customized search capabilities across all possible covered calls but here are a couple of examples for ESPR (prices last updated Tue 4:16 PM ET):

Want to make money with covered calls?  Sign Up For A Free Trial

Esperion Therapeutics, Inc. is a commercial-stage biopharmaceutical leader specializing in non-statin lipid-lowering therapies. The company’s flagship products, NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), are the first oral, once-daily, non-statin medicines approved in over a decade to reduce LDL-cholesterol. By targeting the ATP-citrate lyase (ACLY) pathway, the firm provides a unique mechanism of action that works upstream of the cholesterol synthesis process, offering a critical alternative for millions of patients who are statin-intolerant or statin-resistant.

Core Business and CLEAR Outcomes Success

The company’s growth trajectory was significantly accelerated by the results of the "CLEAR Outcomes" trial, which demonstrated that bempedoic acid reduces the risk of major adverse cardiovascular events (MACE). In early 2026, the firm reported record revenue driven by expanded FDA labels that now include primary prevention in high-risk patients—a move that broadened the addressable market to over 70 million individuals in the U.S. alone. Additionally, the firm is advancing a robust pipeline featuring "Triple Combination" products (Bempedoic Acid, Ezetimibe, and a Statin) and ESP-2001, a next-generation ACLY inhibitor designed to treat rare and orphan diseases such as Primary Sclerosing Cholangitis.

Competitive Landscape

The cardiovascular and lipid-management market is highly competitive, with the company vying against established injectable biologics and emerging oral therapies. Key competitors include:

1. Amgen Inc.: A global biotechnology giant and the manufacturer of Repatha, a leading PCSK9 inhibitor. They compete through a dominant market share in the injectable cholesterol-lowering space and extensive commercial resources.
2. Ionis Pharmaceuticals, Inc.: A leader in RNA-targeted therapeutics. They compete through their development of antisense medicines targeting cardiovascular risk factors like Lp(a) and Angiopoietin-like 3 (ANGPTL3).
3. Nurix Therapeutics, Inc.: A biopharmaceutical company focused on protein modulation. They compete for investment capital and research talent within the broader therapeutic landscape targeting chronic and life-threatening diseases.
4. Regeneron Pharmaceuticals: The co-developer of Praluent, another major PCSK9 inhibitor. They compete for market access and physician mindshare among patients requiring aggressive LDL-C reduction beyond standard statin therapy.

Strategic Outlook and Innovation

The firm is prioritizing a "Global Expansion" strategy, leveraging its international partnerships—most notably with Otsuka in Japan and Daiichi Sankyo in Europe—to drive milestone payments and royalty revenue. Strategic efforts in 2026 are focused on the integration of its recent Corstasis Therapeutics acquisition, which added Enbumyst (bumetanide nasal spray) to its cardiovascular franchise. By maintaining a disciplined approach to operating expenses and utilizing its strengthened balance sheet to retire high-cost debt, the company aims to achieve sustained profitability. Management remains committed to establishing bempedoic acid as the global standard of care for non-statin lipid management.

Want more examples? ESPO Covered Calls | ESRT Covered Calls